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Abstract
Legionella pneumophila, the causative agent of Legionnaires’ disease, invades and replicates within macrophages and
protozoan cells inside a vacuole. The type IVB Icm/Dot secretion system is necessary for the translocation of effector
proteins that modulate vesicle trafficking pathways in the host cell, thus avoiding phagosome-lysosome fusion. The
Legionella VipA effector was previously identified by its ability to interfere with organelle trafficking in the Multivesicular
Body (MVB) pathway when ectopically expressed in yeast. In this study, we show that VipA binds actin in vitro and directly
polymerizes microfilaments without the requirement of additional proteins, displaying properties distinct from other
bacterial actin nucleators. Microscopy studies revealed that fluorescently tagged VipA variants localize to puncta in
eukaryotic cells. In yeast these puncta are associated with actin-rich regions and components of the Multivesicular Body
pathway such as endosomes and the MVB-associated protein Bro1. During macrophage infection, native translocated VipA
associated with actin patches and early endosomes. When ectopically expressed in mammalian cells, VipA-GFP displayed a
similar distribution ruling out the requirement of additional effectors for binding to its eukaryotic targets. Interestingly, a
mutant form of VipA, VipA-1, that does not interfere with organelle trafficking is also defective in actin binding as well as
association with early endosomes and shows a homogeneous cytosolic localization. These results show that the ability of
VipA to bind actin is related to its association with a specific subcellular location as well as its role in modulating organelle
trafficking pathways. VipA constitutes a novel type of actin nucleator that may contribute to the intracellular lifestyle of
Legionella by altering cytoskeleton dynamics to target host cell pathways.
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Introduction
The gram-negative bacterium Legionella pneumophila is the
causative agent of a severe type of pneumonia known as
Legionnaires’ disease [1]. Infection of mammalian alveolar
macrophages is believed to be largely accidental and occurs after
inhalation of aerosols originating from contaminated water
sources, where the intracellular pathogen thrives within its natural
protozoan hosts. After phagocytosis, Legionella replicates in a
specialized vacuole that avoids the endocytic pathway and
supports bacterial replication [2–4]. The type IVB Icm/Dot
(Intracellular Multiplication/Defective Organelle Trafficking)
translocation system is essential for the processes that prevent
the phago-lysosome fusion [5–11]. Effector proteins injected into
the host cell by the Icm/Dot T4BSS are presumed to modify
trafficking pathways thus avoiding bacterial degradation and
promoting the formation of a replication-competent Legionella-
containing vacuole (LCV). Although to date approximately
300 Icm/Dot substrates have been identified, the functions of
most effectors remain unknown. With few exceptions, the absence
of one effector does not impair intracellular growth, an occurrence
believed to be due to functional redundancy among effectors and/
or host cell targets proteins or pathways. In fact, a recent study has
demonstrated that a simultaneous deletion of 31% of known
Legionella Type IVB substrates minimally affected intracellular
growth in mouse macrophages [12]. Therefore, classical forward
and reverse bacterial genetics have been mostly ineffective in
determining the functions and contributions of effectors to
intracellular events during infection. Thus alternative approaches
such as bioinformatics and biochemistry have been used to
elucidate the roles of translocated effectors in a small number of
cases.
The conserved organelle trafficking pathways between Saccha-
romyces cerevisiae and higher eukaryotes, its amenability for genetic
manipulation and extensive library of mutants and strains
expressing fluorescently-tagged proteins make yeast an attractive
model for studying the functions of pathogen effectors. A successful
strategy relied on the ectopic expression of Legionella genes in S.
cerevisiae and screening for mistrafficking of proteins to the vacuole
(Vacuolar Protein Sorting/VPS). One of the Legionella effectors
leading to a Vps
2 phenotype is the VipA protein (VPS inhibitor
protein A). We previously showed that in yeast the VipA-derived
interference in organelle trafficking was related to the Multivesic-
ular Body (MVB) Pathway, and that VipA is a bona fide Icm/Dot
substrate translocated into macrophages [13].
PLoS Pathogens | www.plospathogens.org 1 February 2012 | Volume 8 | Issue 2 | e1002546In this work we sought to functionally characterize VipA using
in vivo and in vitro approaches. We found that VipA binds actin and
directly enhances its polymerization in vitro. During infection of
macrophages, translocated VipA localizes in punctate structures
that associate with filamentous actin and early endosomes.
Similarly, hybrid VipA-GFP and VipA-mCherry localize in
puncta when ectopically expressed in both mammalian and yeast
cells. In budding yeast the puncta are often associated with the
vacuole membrane, reminiscent of the pre-vacuolar compartment
seen in vpsE mutants defective for MVB formation, and co-localize
with actin-rich structures/organelles, such as the bud-neck,
endosomes or cortical actin patches. In mammalian cells, VipA-
EGFP puncta co-localize with early endosomes and actin patches,
but not other components of the endosomal or secretory pathways.
In contrast, a VipA mutant (VipA-1) that no longer causes a Vps
2
phenotype in yeast displays a homogeneous cytosolic distribution
and is defective in actin binding in vitro.
These results show that Legionella effector VipA associates with
components of the endocytic pathway and that this function is
linked to its modulation of actin dynamics, suggesting a
mechanism of interference with host cell organelle trafficking
pathways during infection.
Materials and Methods
Strains and media
L. pneumophila, S. cerevisiae and E. coli strains used in this work are
listed in Table S1. Bacterial strains were grown as previously
described [14]. Deletion of vipA in strain LPIF3 was generated by
natural transformation of KS79 [15] with a DNA fragment
containing PCR products of a kanamycin resistance cassette and
flanking regions of vipA. The PCR products were synthesized by
long-flanking homology PCR [16] using primers IF04, IF05, IF06
and IF07 (see Table S2).
Plasmid construction
Plasmids and oligonucleotides used in this study are listed in
Table S2. For expression of GFP tagged proteins in mammalian
cells, plasmids pIF203 and pIF213 were constructed. PCR
amplification of vipA and vipA-1 mutant was carried out using as
template chromosomal DNA from strain JR32 and plasmid DNA
pET15b-vipA-1, respectively. Oligonucleotides IF02 and IF03
allowed the introduction of an XhoI site and a Kozak consensus
sequence immediately upstream the 59 end of the gene, and a
BamHI site at the 39end. PCR products were sub-cloned at the
same sites of pEGFP-N1 (Clontech) generating translational
fusions of the vipA alleles to EGFP under the transcriptional
control of the CMV I/E promoter.
For expression of GFP fusion proteins in yeast, plasmids pIF206
and pIF209 were generated by PCR amplification of vipA and
vipA-1, respectively, using the same templates as above and
oligonucleotides IF08 and IF09. The PCR products were digested
with BamHI and HindIII and inserted into the same sites of
pKS84 [15]. In order to construct similar fusions to mCherry, a
derivative of pKS84 was engineered in which the URA3 marker
was substituted by LEU2 and GFP replaced by mCherry. The
exchange of the marker was made by PCR amplification from
pACT2-1 (Clontech) with oligos IF37 and IF38, digestion of the
product with SalI and XmaI and subcloning in the same sites of
pKS84. Insertion of mCherry was then carried out by subcloning a
PCR product obtained by amplification from pXDC50 with oligos
IF39 and IF40 and digestion with HindIII and SalI, leading to a
Pgal-mCherry fusion in plasmid pIF215. Two DNA fragments
containing vipA or vipA-1 were removed from pIF206 or pIF209
(see above) by digestion with BamHI and HindIII and inserted in
the same sites of pIF215, yielding pIF216 and pIF217 carrying the
vipA-mCherry fusions.
For expression of his-tagged proteins in E. coli, wild-type or
mutant vipA-1 alleles were amplified using primers NSP22 and
NSP23, containing NdeI and BamHI sites. The PCR products
were digested with these enzymes and inserted in the same sites of
pET15b (Novagen), and plasmids pET15b-VipA and pET15b-
VipA-1 were obtained. Plasmid pNSvipA was constructed by
amplifying vipA with oligos NSP29 and NSP30, both containing
SalI sites. The PCR product was digested with this enzyme and
cloned in the SalI site of pNS00 [13].
vipA linker mutagenesis
Mutagenesis was performed using the GPS Linker Scanning
System according to the manufacturer’s instructions (New England
Biolabs) and plasmid pNSvipA used as a template (see above). The
transposition reaction was performed with 1.5 mg pNSvipA
incubated with 20 ng pGPS4 and 1 ml TnsABC. Dilutions of the
reaction were used to transform ElectroTen Blue E. coli (Stratagene)
by electroporation and plated on LB+Carbenicillin+Chloramphe-
nicol. Plasmid DNA was prepared from approximately 25000
scraped colonies, transformed into the yeast strain NSY01 and
transformants plated on SC-ura/fructose. Invertase overlay was
performed on yeast transformants as previously described [13] and
roughly 14% of colonies were white, indicating a restoration of the
Vps
+ phenotype. 100 of these colonies were isolated, grown
overnight in liquid SC-ura/fructose and plasmid DNA extracted.
Plasmid pools were digested with PmeI to excise the Cm
R marker,
the plasmid backbone gel purified, self-ligated and transformed into
E. coli. Plasmid DNA was extracted from 352 colonies and
transformed into NSY01. Roughly 30% of the colonies were white
on the Invertase Overlay, from which 40 were grown overnight in
liquid SC-ura/fructose, plasmid DNA prepared and sequenced to
map and identify the linker insertion.
Immunodetection of VipA and GFP fusions
For detection of VipA in L. pneumophila, strains were grown
overnight in AYE medium with the appropriate antibiotics.
Author Summary
Legionella pneumophila is a facultative intracellular bacte-
rium that can cause an often fatal type of pneumonia
known as Legionnaires’ disease. In nature, L. pneumophila
is found in both fresh water and soil where it parasitizes
free-living protists. Upon inhalation of contaminated
aerosols, L. pneumophila invades and replicates in alveolar
macrophages, leading to inflammation and development
of the disease. Legionella uses a type IVB secretion system
to translocate effector proteins into the host cell that
modify its trafficking pathways and prevent fusion of the
newly formed phagosome with the lysosome. One of these
effectors is VipA, which, when expressed in yeast interferes
with the Multivesicular Body (MVB) pathway. We found
that VipA protein binds actin and nucleates its polymer-
ization without additional host factors. VipA localizes in
puncta in eukaryotic cells, and these colocalize with actin-
rich regions and endosomes. We demonstrate that the
ability to disrupt the MVB is associated with the capacity to
bind actin. Thus VipA may contribute to the intracellular
lifestyle of L. pneumophila by targeting the cytoskeleton in
order to disrupt normal vacuolar trafficking pathways in
host cells.
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8 cells) were harvested by
centrifugation, sample buffer was added and after SDS-PAGE
the proteins were immunoblotted with affinity-purified rabbit
polyclonal antibody raised against recombinant His6-VipA
(essentially as described by Zhu et al. [17]). For detection of GFP
or GFP fusions in yeast, strains were grown on SC-ura+Fructose
or +Galactose plates for three days at 30uC and several colonies
were picked and grown overnight in identical same liquid medium.
An amount equivalent to OD600 3 in a total volume of 40 mlo f
SDS-Loading Buffer (or OD600 1i n1 5ml in the case of the strain
expressing GFP) was boiled for 5 minutes and run on SDS-PAGE.
Transfer and immunoblotting were performed as above using a
rabbit polyclonal antibody to GFP at a 1:1000 dilution. For
immunoblots of translocated VipA, differentiated THP-1 cells
were infected with L. penumophila strains for 3 hr at an MOI=50.
Cells were lysed by incubation with PBS+Triton X 2% for 15 min
at 4uC. Lysates were centrifuged at 13.000 rpm for 15 min, and
pellet resuspended in the same solution.
Overexpression and purification of His6-VipA and His6-
VipA-1
E. coli BL21(DE3) strains carrying vipA expressing plasmids (see
Table S2) were grown overnight and backdiluted 1:50. At an
OD600,0.6, IPTG (isopropyl b-D-1-thiogalactopyranoside) was
added to a final concentration of 1 mM and growth was continued
for 2 hours. For pull-down assays, pellets were resuspended in
20 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM EDTA,
100 mg.ml
21 PMSF+Protease Inhibitor Cocktail (Sigma), 1 mg.ml
21
lysozyme and incubated for 30 min on ice. Bacteria were lysed using
3 passages in a French Press, lysates were centrifuged at 16000 rpm
and supernatants were transferred to tubes containing Ni-NTA beads
(QIAgen) or loaded on HisTrap FF Columns (GE Healthcare)
connected to a AKTA FPLC system (GE Healthcare), and eluted
with Imidazole gradients.
Tissue culture and growth of cell lines
Acanthamoeba castellanii were cultured in PYG medium at 28uC
without agitation. CHO FccRII and THP-1 cells were grown in
DMEM or RPMI, respectively, supplemented with 2 mM
glutamine and 10% heat-inactivated fetal bovine serum, at 37uC
in a 5% CO2 incubator. Differentiation of monocytes was
accomplished 3 days after the addition of 1 ng.ml
21 of PMA
(phorbol 12-myristate 13-acetate) to the medium.
Mammalian cell immunofluorescence and confocal
microscopy
CHO-FccRII cells [18] were grown, transfected, fixed and
permeabilized for immunofluorescence as described previously
[15]. Actin or DNA staining was carried out by incubating cells
with, respectively, Rhodamine-phalloidin (Sigma, 5 mg.ml
21)o r
DAPI (100 mg.ml
21) during 30 min. Infection of THP-1 mono-
cyte-like cells was carried out as described above using an
Multiplicity of Infection of 50, and cells processed for immuno-
fluorescence (14). For rhodamine-dextran endocytosis assays, the
compound was added at 4 hr post-infection, for 1 hr and chased
for 10, 30, 120 and 240 min, at 1 mg.ml-1. Mouse monoclonal
primary antibodies used were a-EEA1 (BD Biosciences), a-
LAMP1 (UH1), a-ALIX (Biolegend), and aKDEL (Santa Cruz
Biotecnology). Secondary antibodies were goat anti-mouse Alexa-
594 or FITC-labeled (Invitrogen), or a-rabbit Alexa-647 (Invitro-
gen), -TRITC or -FITC (Sigma). The aVipA antibody used in
immunofluorescence assays was previously affinity-purified (see
above). Microscopy was carried out on Laser Scanner Confocal
Microscopes (Zeiss LSM710, Leica SP5 II STED-CW or Leica
TCS SP2).
Colocalization quantification and statistical analysis
Quantitative analysis of colocalization was performed by
calculating the Manders overlap coefficient, corresponding to the
fraction of green pixels (VipA-EGFP signal) that overlap with red
pixels in relation to the total green pixels [19]. For this purpose,
signal intensities for each cell (n.15 for each antibody) were
adjusted in ImageJ and the coefficients determined with the
plugin JACoP [20]. Statistical significance was determined with
unpaired t test, and p values obtained are indicated (**, p,0.01;
***, p,0.001).
Yeast microscopy and FM4-64 staining
S. cerevisiae cells expressing GFP or mCherry fusion proteins
were grown in plates with SC-Ura/-Leu/-Ura-Leu supplemented
with 2% fructose at 30uC for 3 days. Several colonies were
inoculated in identical liquid medium supplemented with 2%
galactose and grown overnight. The next day the cultures were
diluted in the same medium to an OD600=0.3, and grown to an
OD600=0.5. FM4-64 staining was performed essentially as
previously described [15]. Cells were mounted on agarose pads
and visualized on a Laser Scanner Confocal Microscope (Zeiss
LSM710).
Pull-down assays
For pull-down assays, U937 monocyte post-nuclear supernatants
(PNS) were prepared by harvesting 2610
8 U937 cells grown in
suspension in RPMI+Glu+10%FBS. Cells were lysed by addition of
10 ml50 mMTris-HclpH 8,150 mMNaCl,0.1 mMEDTA,0.5%
NP-40, 1 mM DTT, 0.1 mM NaVO4,1 0 0mg.ml
21 PMSF+Pro-
tease Inhibitor Cocktail (Sigma). Lysis was accomplished by 1 hour
incubation on ice and centrifugation at 4000 rpm for 30 min. 10 ml
U937 PNS were mixed with 100 ml Ni-NTA beads loaded with
approximately 100 mg his-tagged bait proteins, incubated at 4uCa n d
washed with His buffer (20 mM Tris-HCl pH 8.0, 300 mM NaCl,
10% Glycerol, 100 mg.ml
21 PMSF)+40 mM Imidazole. Beads were
a p p l i e dt oaB i o R a dc o l u m n ,w a s h e da g a i na n de l u t e dw i t h
HisBuffer+500 mM Imidazole. Eluates were collected, mixed with
Protein Sample Buffer and analyzed by SDS-PAGE followed by
either Coomassie staining or Western blot. Differential protein bands
in eluates that were absent in His-FabI and Beads only pull-downs,
and did not react with antibody against polyHistidine were excised,
digested with trypsinand analyzed by Liquid Chromatography/Mass
Spectrometry (LC/MS). For Western blotting 1:5000 dilutions of
monoclonal antibody against either actin or polyHistidine (Sigma)
were used.
Actin polymerization assays
G-actin and Pyrene-labeled G-actin (Cytoskeleton, .99% pure)
were prepared as indicated by the manufacturer and kept in G-
actin buffer (Tris-Cl 5 mM, CaCl2 0.2 mM, ATP 0.2 mM, DTT
1 mM). Before polymerization, conversion to Mg-actin was
accomplished by addition of EGTA to 0.2 mM and MgCl2 to
50 mM and incubation for 2 min at room temperature. Polymer-
ization assays were made on black bottom microplates and
fluorescence read in a microplate reader equipped with an injector
(Infinite M200, Tecan). Values were obtained using an excitation
wavelength of 365 nm and emission of 407 nm, and recorded at
10 sec intervals. Data were collected with Magellan software v6.4
(Tecan) and then processed in Excel (Microsoft). Reactions
contained 2 mM actin (10% Pyrene-labeled), and were initiated
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KCl 50 mM, MgCl2 1 mM, EGTA 1 mM). Purified His6-VipA or
His6-VipA-1 in G-Mg buffer (G-actin buffer with 0.1 mM MgCl2
instead of Cacl2) were added as indicated.
To measure elongation, actin seeds were prepared as follows
(adapted from [21]). Actin was resuspended in G-actin buffer to a
final concentration of 15 mM, converted to Mg-actin for 20 min
and polymerization induced by addition of KMEI Polymerization
buffer (see above) and incubation for 2 hr at room temperature.
To stabilize filaments, actin was diluted to 5 mM in the presence of
5 mM of phalloidin for 5 min. The polymerized actin was
recovered after centrifugation for 20 min at 90,000 rpm and
4uC in a TLA100 rotor and these protected filaments ressus-
pended in G-actin buffer and used in elongation assays with 1 mM
G-actin. Filament concentration and rate of monomer addition
were calculated as described previously [22].
Accession numbers
Swissprot IDs of proteins: Legionella pneumophila VipA, Q5C8M7;
Chlamydia trachomatis TARP, Q6GX35; Salmonella enterica serovar
typhimurium SipC, Q56020, and SipA, P0CL52; Vibrio parahaemo-
lyticus VopL, B9A807, and Vibrio cholerae VopF, B5AN40; Rickettsia
conorii Sca2, Q92JF7; Saccharomyces cerevisiae Bro1, P48582; Homo
sapiens Alix, Q8WUM4.
Results
L. pneumophila effector VipA binds actin in vitro
In previous work aimed at identifying new effectors [13],
disruption of organelle trafficking was observed when VipA was
ectopically expressed in yeast, raising the possibility that an
interaction between VipA and host cell proteins could be involved
in the process. We sought to identify eukaryotic binding partners
for VipA in macrophages by in vitro assays using purified VipA as
bait to pull-down proteins from U937 human monocyte-like cell
extracts. For this purpose, a recombinant version of VipA carrying
a 6-histidine tag at its N-terminal region (His6-VipA) was
constructed in plasmid pET15b (Novagen) and purified by Ni-
NTA affinity chromatography. A post-nuclear supernatant was
prepared from U937 cells and incubated with Ni-NTA agarose
beads, preloaded either with His6-VipA or an irrelevant protein,
His6-FabI, the L. pneumophila enoyl acyl CoA reductase protein,
used as negative control for the interaction as it is not translocated
into the host cell [23]. Bound proteins were eluted with 500 mM
imidazole, separated by SDS-PAGE and analyzed by Coomassie
staining (Figure 1A). A 42-kDa band that co-eluted with VipA but
was absent in the FabI eluate and did not react with an antibody
against polyHistidine (data not shown) was excised and identified
as b-actin by Liquid Chromatography/Mass Spectrometry (LC/
MS). This result was confirmed with a Western-blot using a
monoclonal antibody against actin (Figure 1B). To test if the
interaction between VipA and actin was direct, additional pull-
down assays were performed using His6-VipA and increasing
concentrations of purified monomeric G-actin (Figure 1C). The
results show that actin bound to VipA directly, without the
requirement of any additional host factor.
Interference of VipA in trafficking pathways is linked to
actin binding
The finding that VipA interacted directly with actin in vitro
suggested a mechanistic basis for the ability of the protein to affect
vesicle trafficking pathways in yeast, as actin is involved in
numerous membrane trafficking processes [24]. To test if the
ability of VipA to disrupt trafficking depended on its interaction
with actin, we generated linker mutant alleles of vipA using the
transposon-based GPS system (New England Biolabs). This
procedure ultimately introduces 15-bp insertions in the target
gene, of which 1/3 result in the insertion of a stop codon and 2/3
in the in-frame insertion of five amino acids. A plasmid harboring
vipA was mutagenized and the library of mutants (approximately
25000 colonies) transformed into yeast strain NSY01, used as a
reporter for screening Vacuolar Protein Sorting defects (Vps
2
phenotype) [13]. This strain produces the hybrid protein
Carboxypeptidase Y-Invertase, which travels to the vacuole in
wild-type yeast but can be missorted to the cell surface if vacuolar
protein trafficking is disrupted, which is the case when wild-type
VipA is ectopically expressed. The excreted enzyme hydrolyses
sucrose present in the medium that can be detected by the brown
color of the colonies in a particular screening medium (Vps
2
phenotype; see [25]). In this work, we were interested in isolating
vipA mutants that no longer disrupted vacuolar traffic, thus leading
to the formation of white/Vps
+ colonies. These colonies were
isolated from transformants of the vipA linker library, and the
corresponding plasmids sequenced to map the insertions. Five
different in-frame insertions were identified disrupting the ability
of the protein to cause a Vps
2 phenotype (Figure 2A). All five
VipA mutant proteins were stably expressed in yeast at levels
identical to wild-type (data not shown). Interestingly, all insertions
mapped between codons 67 and 98, just upstream of a sequence
encoding a predicted coiled-coil domain located between residues
137 and 200. Sequence analysis of this region and additional
investigation of the entire protein sequence did not reveal further
homologies to known domains or motifs, although we noted a high
occurrence of prolines in the C-terminal region of VipA.
To further understand the importance of the N-terminal region,
one of these mutant proteins (VipA-1, insertion at residue 67) was
expressed and purified as a his-tagged fusion protein (His6-VipA-
1), displaying expression and solubility levels similar to wild-type
VipA. Its ability to bind actin was tested as above in pull-down
assays using U937 cell extracts, where a significant decrease in
affinity for monomeric actin was observed (Figure 2B). Taken
together, these results show that the ability of VipA to disrupt
vacuolar trafficking in yeast and its ability to bind actin are linked.
This result is inconsistent with a non-specific association of actin
and VipA.
Direct enhancement of actin polymerization by VipA in
vitro
To find out whether VipA had any effect on the assembly of
actin filaments we used pyrene-actin polymerization assays.
Fluorescence of pyrene-actin increases significantly when G-actin
monomers are incorporated into a filament, permitting polymer-
ization to be measured in real-time. In reactions containing 2 mM
actin (10% pyrene-labeled), His6-VipA stimulated actin polymer-
ization at nanomolar concentrations in a dose-dependent manner
(Figure 3A). Saturation occurred at approximately 100 nM VipA,
a concentration that increased the actin polymerization rate by
approximately 3-fold (Figure 3A, right panel). This effect on
microfilament polymerization is not as potent as the nucleation of
actin by the Arp2/3 complex activated by WASP-VCA
(Figure 3B), or the mouse formin mDia2 (Figure 3C). Also, in
contrast to the case of other bacterial effectors, His6-VipA does not
activate Arp2/3-mediated actin polymerization, as the effect seen
in the presence of inactive Arp2/3 and VipA is additive of the two
individual effects. The VipA-1 mutant displayed only a small effect
on the assembly of actin filaments, in the same order of magnitude
of inactive Arp2/3, even at high concentrations (Figure 3B).
Eukaryotic Targets of Legionella pneumophila Effector VipA
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kinetics. The initial and limiting step, nucleation, occurs very
slowly and leads to the formation of actin trimers, whereas the
subsequent elongation of the filament takes place at a much higher
rate. The observed shorter duration of the initial lag phase in the
presence of VipA was consistent with a role in enhancing actin
nucleation. To find out if VipA was also affecting elongation, we
carried out polymerization assays with actin seeds. In these assays
all polymerization occurs from short preformed actin filaments,
and thus increases in fluorescence are not due to de novo actin
nucleation. As shown in Figure 3C VipA enhanced slightly but
reproducibly the elongation rate of the small filaments. Cytocha-
lasin D, a well-characterized filament barbed-end capper used
here as a negative control, lead to a complete halt in elongation.
The effect mediated by VipA during filament elongation could
not, however, account for the overall increase in actin polymer-
ization observed above (Figures 3A and B), which indicates VipA is
acting predominantly as a nucleator.
Taken together, the data obtained with the in vitro actin
polymerization assays shows that VipA is able to enhance actin
polymerization without the requirement of additional proteins.
Moreover, these results indicate the effector uses a mechanism that
favors nucleation and moderately increases the rate of addition of
monomers during elongation.
Figure 1. In vitro interaction analysis between His6-VipA and actin by pull-down assays. A. U937 cell Post-Nuclear Supernatants (U937
PNS) were incubated with Ni-NTA agarose beads preloaded with His6-VipA or His6-FabI (see Materials and Methods for details). After washing, bound
proteins were eluted with 500 mM Imidazole. Samples containing preloaded beads or eluates were resolved by SDS-PAGE and bands visualized by
Coomassie staining. The differential band appearing in the VipA eluate (arrow) was excised and identified by LC/MS as b-actin. B. Similarly prepared
samples were resolved by SDS-PAGE, transferred to nitrocellulose and immunoblotted with an anti-actin monoclonal antibody (a-actin). C. Ni-NTA
agarose beads preloaded with His6-FabI or His6-VipA were incubated with increasing concentrations of purified G-actin, washed and eluted. Eluates
were resolved by SDS-PAGE, transferred to nitrocellulose and Western-blotted with an anti-histidine antibody (a-polyHis, panel above) or an anti-actin
monoclonal antibody (a-actin, panel below).
doi:10.1371/journal.ppat.1002546.g001
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castellanii and macrophages
The L. pneumophila genome encodes approximately 300 effector
proteins that are translocated to the host cell during infection.
Surprisingly the vast majority of effector genes are dispensable for
intracellular replication and yield no obvious phenotype when
deleted. In order to determine if VipA is essential for infection of
host cells, the vipA gene was deleted from Legionella strain KS79.
The wild-type vipA allele was substituted by a kanamycin-
resistance cassette and the absence of VipA protein in the
resulting strain LPIF3 was confirmed by Western immunoblot
using a polyclonal anti-VipA antibody (Figure S1A). Infection of
THP-1 macrophages and the amoeba A. castellanii was carried out
with Legionella strains KS79 and LPIF3 harboring plasmid
pXDC31 (Table S2), in which GFP expression is driven by the
IPTG-inducible Ptac promoter. Thus, intracellular bacterial
replication can be followed by real time monitoring of GFP
fluorescence measurements [26]. In addition, the translocation-
defective dotA mutant strain containing the same plasmid was used
as a negative control for intracellular growth. Replication in A.
castellanii was not affected by deletion of vipA, and identical results
were obtained using THP-1 macrophages as hosts (Figure S1B;
data not shown). As a more subtle effect in the initial phase of
phagocytosis may be difficult to detect in this assay, gentamicin
protection assays were carried out to measure entry into host cells.
Similarly, no significant difference was observed between the
number of intracellular bacteria from wild-type or vipA strains
(data not shown).
Figure 2. Vps
+ phenotype of VipA mutants is linked to actin binding. A. Primary sequence of VipA and localization of in-frame insertions in
mutant proteins encoded by the 5 obtained Vps
+ alleles (vipA-1 to vipA-5). The inserted residues in each allele are shown below the sequence. The
predicted secondary structure is depicted, with alpha-helices as rectangles, beta-strands as block arrows (PSIPRED v2.6 software [54] and the central
coiled-coil motif as dashed line (SMART software [55,56] B. Pull-down assays with G-actin and wild-type VipA or mutant VipA-1 proteins. U937 Post-
nuclear supernatants were incubated with Ni-NTA agarose beads preloaded with His6-VipA or His6-VipA-1, washed and eluted with 500 mM
Imidazole. Eluates were resolved by SDS-PAGE, transferred to nitrocellulose and analyzed by Western-blot with monoclonal antibodies against
polyHistidine (a-polyHis) or against actin (a-Actin).
doi:10.1371/journal.ppat.1002546.g002
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PLoS Pathogens | www.plospathogens.org 6 February 2012 | Volume 8 | Issue 2 | e1002546Figure 3. In vitro actin polymerization assays. Samples contained 2 mM monomeric actin (10% Pyrene-actin) and fluorescence (expressed in
Arbitrary Units, AU) was measured over time after initiation of polymerization. A. The displayed concentrations of His6-VipA were added to the
samples and polymerization initiated. The graph on the right is a plot of the average and standard deviation for the rates of actin polymerization for
each His6-VipA concentration. Velocities were determined for the interval 600–1200 s using the results of two independent experiments. B and C.
Actin samples contained 10 nM Arp2/3 complex, 400 nM WASP-VCA (Cytoskeleton), 400 nM His6-VipA, 560 nM His6-VipA-1 and 10 nM of mDia2
where indicated. D. Elongation of filaments was carried out using phalloidin-stabilized actin seeds and 1 mM of G-actin (10% Py-labeled), in the
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PLoS Pathogens | www.plospathogens.org 7 February 2012 | Volume 8 | Issue 2 | e1002546VipA forms puncta in yeast that localize to actin-rich
regions
To gain further insight into the function of VipA we analysed its
subcellular localization in eukaryotic cells. For this purpose initial
studies were performed in S. cerevisiae, in which the Vps
2
phenotype had led to vipA identification. S. cerevisiae strain
NSY01 (see above) was transformed with plasmids carrying C-
terminal GFP fusions of either wild-type VipA or mutant VipA-1
under the control of the galactose-inducible Pgal promoter. In the
resulting strains, expression of the ,70 kDa recombinant proteins
in the presence of the inducing sugar was confirmed by Western-
blot of the cell extracts using an anti-GFP antibody (Figure 4A).
Laser Scanning Confocal Microscopy analysis revealed the
localization of VipA-GFP in puncta in yeast cells (Figure 4B),
whereas the VipA-1-GFP mutant protein exhibited homogeneous
cytosolic distribution, similar to GFP alone. Interestingly,
approximately half of the VipA puncta were associated with the
mother-bud neck in dividing cells, a site containing the cytokinetic
ring and enriched in actin filaments, which is consistent with the
ability of VipA to interact with actin in vitro (see above). Thus, the
association of VipA with other actin-rich structures was investi-
gated. In S. cerevisiae, visible F-actin structures consist of patches,
cables and rings. Patches are highly motile punctate structures that
form at the cell cortex, mediate endocytosis and contain numerous
actin-associated proteins. After endosome internalization they
transition to a phase of rapid movement that depends on their
transport along actin cables away from the cell membrane
[27–29]. Actin cables consist of bundles of F-actin aligned along
the mother-bud axis and serve as tracks for the movement of
secretory vesicles, mitochondria, Golgi, and vacuoles from the
mother cell to the growing bud [30,31]. Association of VipA-
mCherry with actin in patches and cables was assessed by
colocalization studies with two actin markers: Abp1-GFP, which
binds F-actin patches in endosomal sites, and Abp140-GFP, which
associates with microfilaments in both patches and cables
[27,32,33]. The distribution of VipA-mCherry and VipA-1-
mCherry was identical to the observed above with the VipA-
GFP and VipA-1-GFP fusions, respectively (Figure 4C). Coloca-
lization between VipA and actin structures was observed in the
case of Abp1-containing endosomes (Figure 4C, left panel) and for
Abp140-associated patches, but not cables (Figure 4C, right panel).
The presence and distribution of these markers was not affected by
the presence of either VipA or VipA-1-mCherry. These results
show that the puncta formed by VipA in yeast are located in sites
containing a high array of actin filaments, namely the cytokinetic
ring and cortical patches, and that the vipA-1 mutation that
decreased the affinity of VipA for actin in vitro also abolished its
targeting to these locations.
VipA associates with components of the yeast MVB
pathway
T h ei n t e r f e r e n c eo fV i p Ai nt h ef o r m a t i o no ft h eM V Bi ny e a s t
[13] strongly hinted its interaction with one or more components
of this pathway. MVBs are present in both the Endocytic and
Secretory/Biosynthetic pathways and result from the invagina-
tion and budding of the endosome membrane, and eventually
fuse and deliver their cargo to the vacuole/lysosome. We initially
tested an interaction with the yeast vacuole using the styryl dye
FM4-64, which stains the vacuole membrane after being
internalized by endocytosis [34]. Staining of cells producing
VipA-GFP revealed that approximately 70% of the VipA puncta
were associated with the vacuole membrane and co-localized with
an abnormal pre-vacuolar compartment observed previously in
strains expressing VipA (Figure 5A; [13]). This structure is
identical to the one characteristic of class E vps mutants, where
defective MVB formation leads to the inability of endocytosed
cargo to fuse completely with the vacuole [35,36]. This failure is
caused mainly by defects in packaging of the cargo into
intralumenal vesicles of MVBs, which is carried out by the
sequential action of proteins composing the ESCRT 0-III
complexes (Endosomal Sorting Complex Required for Trans-
port). One of the proteins involved in these late steps of the MVB
pathway is Bro1, a cytoplasmic yeast protein that transiently
associates with endosomes, where it is required for the formation
of intralumenal vesicles. We assessed VipA-mCherry colocaliza-
tion with Bro1-GFP and verified that approximately 37% of
VipA puncta colocalized with Bro1-GFP (Figure 5B), confirming
an association of the effector with this protein component of the
MVB.
Taken together, these results show that VipA associates with
components of the yeast MVB pathway, namely Bro1-containing
endosomes and the vacuole. Moreover, they suggest that the
previously observed effect of VipA on mistrafficking of vacuolar
proteins could be due to a defect on late steps on the MVB
pathway wherein fusion of endosomes with the vacuole occurs.
VipA colocalizes with host cell actin and early endosomes
but not the LCV during macrophage infection
In order to assess the subcellular localization of VipA in host
cells under physiological conditions, infection of THP-1 monocyte-
like cells was carried out, cells fixed at several time points post-
infection, processed for immunofluorescence using a polyclonal
anti-VipA antibody and analysed using Laser Scanning Confocal
Microscopy. After infection with wild-type strain L. pneumophila
JR32, VipA was found in diverse structures inside the host cell,
which varied in size from puncta to larger formations (Figures 6
and 7). VipA was not associated with the LCV at any time point
from 30 min to 14 hr after uptake (Figure 6A and B; data not
shown). To assess the localization of the VipA-1 mutant, L.
pneumophila vipA null-mutant background strains were constructed
carrying plasmids encoding IPTG-inducible copies of either the
wild-type or the mutant vipA allele (respectively, DvipA
pMMB207c-Ptac-vipA
+ or DvipA pMMB207c-Ptac-vipA-1). Infec-
tion with the strain carrying Ptac-vipA
+ led to a similar distribution
of the effector as observed in JR32, although the protein was
observed in the host cell earlier after uptake. This localization was
lost in the vipA-1 mutant, in which the effector was translocated in
levels similar to the wild-type (Figure 6C) and homogeneously
distributed in the host cell cytosol (Figures 6A and 7A).
In order to examine the colocalization of translocated VipA
during the course of infection with endosomes and actin, infected
cells were stained with respectively, an anti-EEA-1 antibody and
rhodamine-phalloidin, a fluorescently-labeled protein that specif-
ically binds F-actin. Colocalization was observed with both
markers and increased over time, reaching the highest values at
8 hours post-infection (Figures 6B and 7A; data not shown). To
determine the degree of colocalization with these two cell
components, quantitative analysis was performed by calculating
the Manders overlap coefficient, a commonly used approach for
presence of His6-VipA-1 (100 nM) or Cytochalasin D (100 nM). Determination of F-actin concentration and rates of polymerization are described in
Materials and Methods.
doi:10.1371/journal.ppat.1002546.g003
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PLoS Pathogens | www.plospathogens.org 8 February 2012 | Volume 8 | Issue 2 | e1002546Figure 4. Localization of VipA-GFP in S. cerevisiae.A .Yeast strains producing GFP, VipA-GFP or VipA-1-GFP (respectively strains SCIF00, SCIF01
and SCIF02) were grown in medium with fructose or galactose to an OD600,0.5. Equivalent amounts of cell lysates were run on SDS-PAGE and
analysed by Western-blot using an anti-GFP polyclonal antibody [57]. The arrow points to the bands corresponding to VipA-GFP or VipA-1-GFP fusion
proteins. B. The same strains grown in galactose were viewed using Laser Scanning Confocal microscopy and representative images are shown (left).
C. Colocalization of VipA-mCherry and actin structures in yeast. Yeast strains producing mCherry, VipA-mCherry or VipA-1-mCherry and Abp1-GFP
(left) or Abp140-GFP (right; see Table S1) were grown and visualized as above.
doi:10.1371/journal.ppat.1002546.g004
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PLoS Pathogens | www.plospathogens.org 9 February 2012 | Volume 8 | Issue 2 | e1002546quantifying colocalization in fluorescence microscopy [19]. Briefly,
in this experiment it corresponds to the fraction of blue pixels
(VipA signal) that overlaps with green or red pixels (EEA-1/Early
Endosome and Rhodamine-phalloidin/F-actin, respectively) (see
Materials and Methods). As shown in Figure 7B, at 8 hr post-
infection an average of 23% of VipA colocalized with EEA-1 and
40% with actin filaments, being these values approximately 10%
higher in the case of the strain carrying Ptac-vipA
+. Notably, in
some cells more than 80% of VipA was associated with EEA-1 or
actin (Figure 7B), often simultaneously with both (see also enlarged
areas of Figure 7A), suggesting a dynamic interaction among these
components.
Figure 5. VipA associates with components of the yeast MVB pathway. A. For vacuole staining, S. cerevisiae strains were grown as above
(see legend of Figure 4), harvested and additionally pulse-chased with N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenylhexatrienyl)-
pyridinium dibromide (FM4-64). B. Strains carrying the fusions Bro1-GFP (left) and mCherry, VipA-mCherry or VipA-1-mCherry were grown and
visualized as above.
doi:10.1371/journal.ppat.1002546.g005
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PLoS Pathogens | www.plospathogens.org 10 February 2012 | Volume 8 | Issue 2 | e1002546Figure 6. Localization of translocated VipA and VipA-1 during infection of THP-1 macrophages. THP-1 macrophages were infected with L.
pneumophila strains (JR32, DvipA, DvipA pMMB207c-Ptac-vipA or DvipA pMMB207c-Ptac-vipA-1) with an MOI=50 for 8 hours. Immunofluorescence was
carried out as described (Materials and Methods). DNA was stained with DAPI and VipA with a purified polyclonal anti-VipA antibody. A. and F-actin was
stained with Rhodamine-phalloidin. B. Representative confocal microscopy images are shown. C. Immunoblot of samples containing lysates of THP-1
macrophages infectedfor 3 hrwiththe indicated L.pneumophila strains atanMOI=50(seeMaterialandMethods). P,lysatepellet; SN, lysatesupernatant.
doi:10.1371/journal.ppat.1002546.g006
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PLoS Pathogens | www.plospathogens.org 11 February 2012 | Volume 8 | Issue 2 | e1002546We addressed the possible interference of VipA in host cell
endocytic trafficking in several ways. Firstly, we looked for a defect
in endocytic internalization of rhodamine-dextran in THP-1
macrophages previously infected with L. pneumophila wild-type or
DvipA. In this experiment, we compared the total rhodamine
fluorescence in both types of infected cells, and we investigated
possible delays in trafficking of rhodamine-dextran by visualizing
colocalization of this dye with anti-EEA-1 antibody over time.
However, in neither case a significant difference was apparent,
suggesting that endocytic internalization and early endosome
Figure 7. Colocalization of VipA with host cell early endosomes and actin in macrophage infection. A. THP-1 macrophages were
infected as above (see Legend of Figure 6 and Materials and Methods). F-Actin was stained with Rhodamine-phalloidin and Early Endosomes using an
aEEA-1 antibody. B. Quantification of colocalization between VipA and F-Actin or EEA-1 was performed by calculating the Manders coefficient using
ImageJ and the Plugin JACoP (see Materials and Methods for details). The Manders coefficient corresponds to the fraction of VipA-GFP or VipA-1-GFP
(blue signal) overlapping with each marker (green or red signal) divided by the total green signal in an image. Filled symbols represent cells
expressing VipA-GFP (n.15), open symbols cells expressing VipA-1-GFP, and bars indicate mean and standard deviation. Statistical analysis was
performed with unpaired t test, and p values obtained are indicated (**, p,0.01; ***, p,0.001).
doi:10.1371/journal.ppat.1002546.g007
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PLoS Pathogens | www.plospathogens.org 12 February 2012 | Volume 8 | Issue 2 | e1002546trafficking is not being affected by the presence of VipA (data not
shown). Additionally, the number and morphology of EEA-1
positive Early Endosomes were identical in these infected cells.
These observations demonstrate that during macrophage
infection, translocated VipA binds actin filaments and early
endosomes in the host cell. To our knowledge, no other currently
identified Legionella effector displays either of these properties.
VipA binding to cellular targets does not require
additional Legionella effectors
The previous macrophage infection experiments did not
exclude the possibility that additional Legionella effectors secreted
during infection were required for the correct localization of VipA
upon translocation into the host cell. Thus, in order to analyse
VipA subcellular localization in the absence of other Legionella
proteins, we expressed it ectopically in mammalian CHO cells and
examined its association with microfilaments and early endosomes.
For this purpose, a VipA-EGFP fusion protein was constructed
and its expression placed under the control of the CMV promoter
in a derivative of plasmid pEGFP-N1 (Clontech). The resulting
plasmid was transfected into CHO FccRII cells and these were
fixed and processed after 48 hr. Similarly to what was observed in
yeast and during infection, VipA-EGFP was distributed in puncta
in transiently transfected CHO cells, whereas the mutant VipA-1-
GFP showed homogeneous cytosolic distribution (Figure S2). To
analyse its association with microfilaments, these cells were stained
with Rhodamine-phalloidin. As shown in Figure S2, the degree of
colocalization between VipA and actin was difficult to ascertain
due to the large array of stress fibers present in CHO cells.
Therefore, further visualization was made after the disassembly of
stress fibers with Cytochalasin D, an actin depolymerizing agent
[37,38]. As observed in CHO cells expressing GFP, incubation
with 10 mM Cytochalasin D disrupted the actin cytoskeleton,
changing the organization of actin in the cell from a filament
network to focal accumulations (Figure S2, bottom panel). The
same actin reorganization occurred when VipA-GFP expressing
cells were treated with cytochalasin, but interestingly the VipA
puncta, which did not disassemble but appear to have coalesced
into larger structures, clearly colocalized with the enduring small
cortical actin foci (see colocalization plot in Figure S2). Actin
rearrangements upon cytochalasin treatment were also observed in
cells expressing the VipA-1 mutant fused to GFP, but the cytosolic
distribution of VipA-1-GFP did not alter with cytochalasin
treatment.
The localization of VipA-EGFP with early endosomes was also
tested by immunofluorescence assays with an anti-EEA-1 antibody
(Figure S3A). The degree of colocalization with this marker was on
average approximately 35%, whereas in cells expressing the VipA-
1 mutant the overlap was only 6% (Figure S3E; p,0.001,
unpaired t test), and these values are similar to the ones obtained
during infection (Figure 7).
VipA was shown in this study (see above) to colocalize with
components of the yeast MVB pathway, namely Bro1 containing
endosomes and the vacuole. The protein Alix (also known as AIP-
1) is a component of the MVB and a human counterpart of yeast
Bro1 and interestingly was shown to be involved in the assembly of
microfilaments, constituting a novel link between the MVB and
the actin cytoskeleton [39]. To investigate if VipA associated with
other components of the endosomal/MVB pathway in addition to
early endosomes, we carried out immunofluorescence experiments
in transiently transfected CHO cells and tested colocalization of
VipA-EGFP with LAMP-1 and Alix. As shown in Figures S3 C
and D, some signal overlap was observed with both lysosomes and
Alix. However, the average colocalization was relatively low (15%)
and not distinguishable from the values obtained with the mutant
form of VipA (Figure S3E). In addition, similar results were
obtained when colocalization was tested with the ER marker
KDEL (Figures S3B and E), ruling out an association with the
secretory pathway.
Taken together, these observations demonstrate that VipA
associates with cortical F-actin patches and early endosomes in
mammalian cells, and this occurs independently of other secreted
Legionella effectors. Moreover, ectopically expressed VipA-EGFP
does not colocalize significantly with later components of the
Endosomal/MVB Pathway, such as lysosomes or Alix, or with the
ER.
Discussion
The L. pneumophila effector VipA was identified in previous
studies due to its ability to interfere with organelle trafficking in the
yeast Multivesicular Body (MVB) Pathway [13]. In this work we
have shown that VipA binds actin and is able to polymerize
microfilaments in vitro without the requirement of additional
bacterial or eukaryotic factors (Figure 3). During human
macrophage infection, translocated VipA associates with actin
filaments, as well as with early endosomes (Figure 7). This
subcellular localization was also verified when VipA-GFP or
VipA-mCherry were ectopically expressed in S. cerevisiae and
mammalian CHO cells, showing further that this distribution is
independent of other bacterial effectors (Figures 4, 5, S2 and S3).
In addition, a mutation in VipA that abolished the interference of
the protein in yeast vacuolar trafficking led simultaneously to a
decreased affinity and ability to polymerize actin in vitro (Figures 2,
3) and the ability to associate specifically with the host cell targets
(Figures 4–7, S2 and S3), indicating a function of VipA linking the
actin cytoskeleton and the MVB pathway. Both these functions are
new amongst the pool of L. pneumophila effectors characterized to
date.
Many extra- and intracellular pathogens target host actin as a
means to produce a successful infection. This often involves the
hijacking of the Arp2/3 complex by recruiting or mimicking
nucleation promoting factors (NPFs) by a diverse array of
mechanisms that serve different purposes. Examples include the
movement of Listeria monocytogenes and Shigella within the host
cytosol and cell to cell spread by the formation of actin comet tails
mediated by the effectors ActA [40] and IcsA, respectively [41], or
the formation of actin pedestals in pathogenic E. coli EPEC and
EHEC through the action of the effector Tir [42,43]. However,
the number of known bacterial effectors able to polymerize actin
directly is reduced. Salmonella enterica serovar Typhimurium SipC
nucleates actin with an efficiency identical to the Arp2/3 complex,
and is also able to bundle and crosslink actin filaments [44], and in
Chlamydia the protein TARP forms long unbranched actin
filaments that similarly to SipC seem to facilitate the internaliza-
tion of the pathogen [45]. Contrary to SipC and TARP, Vibrio
parahaemolyticus VopL and VopF polymerize actin much more
potently than activated Arp2/3, leading to the formation of stress
fibers [46] or actin-rich filoform formation in infected cells,
respectively [47]. More recently, Rickettsia rickettsii Sca2 was found
to function as eukaryotic formin mimic and to be involved in actin
tail formation [48]. Several observations support a role of VipA as
an actin nucleator instead of alternative activities that would also
increase actin polymerization, such as decreasing the actin critical
concentration, increasing the elongation rate or severing micro-
filaments. In addition to decreasing the initial polymerization lag
phase, VipA increases the actin polymerization rate, which would
not happen if its effect was in decreasing the actin critical
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Figure 3A). The enhancement of actin polymerization is also not
due to an effect on the elongation rate, which was observable but
weak in assays with actin seeds (Figure 3D). Furthermore, a
possible filament severing activity of VipA was not visible in
Transmission Electron Microscopy experiments (data not shown)
or assays with actin seeds.
When compared to the above mentioned bacterial and
eukaryotic actin nucleators, His6-VipA has lower activity, which
can be due to several reasons. One possibility is that the VipA
protein used in our assays may not be fully active. In fact, like
many actin-binding proteins, VipA may contain auto-regulatory
regions that inhibit its activity or it may need to be activated by
additional bacterial or eukaryotic factor(s) absent in our in vitro
experiments. We cannot also dismiss the possibility that the
presence of the histidine tag may be partially hindering the
protein’s function. Secondly, the unusually high number of
effectors found in Legionella so far (.300) and their observed
functional redundancy raises the possibility that additional
effectors may act in concert with VipA in actin polymerization.
Another explanation could be that the low activity of VipA is
tailored to its predicted function in endosomal trafficking during
infection. Rather than causing major alterations in the host cell
microfilament network, as was proposed for VopL function, VipA
may play a more subtle role where its activity is enough to allow
interference with membrane traffic but not sufficient to disturb
overall cell actin homeostasis.
The primary sequence of VipA contains a central coiled-coil
region and a C-terminal proline-rich region (Figure 2A). Both
motifs are typical mediators of interaction with other proteins, and
Pro-rich regions in particular are involved in binding to profilin.
However, no typical actin-binding motifs such as the WASP-
homology 2 (WH2) domain or Formin-Homology domain 2 (FH2)
are present (reviewed in [50,51]). The absence of either of these
actin-binding motifs in VipA raises the possibility of a novel
molecular mechanism of actin assembly. The analysis of bacterial
effectors that influence host cell actin dynamics has provided
valuable information to understand how eukaryotic NPFs work, as
many share similar modes of action and interacting partners.
Thus, future functional studies of VipA may not only widen the
knowledge concerning virulence factors targeting actin but may
also contribute to a broader comprehension of actin dynamics in
the eukaryotic cell.
Although present in all sequenced genomes of Legionella
pneumophila strains (Philadelphia-1, Corby, Lens, Paris, Alcoy,
570-CO-H and 130b), similarly to most Legionella effectors
studied to date VipA is neither required for intracellular
replication nor uptake (Figure S1B; data not shown). However,
in vivo colocalization experiments in yeast and mammalian cells
provided some clues to its function in the eukaryotic cell. First, in
both types of cells VipA forms punctate structures that localize in
actin-rich regions. In yeast they often associate with the bud-neck,
and with endosomal and cortical actin patches markers Abp1 and
Abp140, respectively (Figure 4). In addition, VipA also colocalized
with the MVB-associated protein Bro1 and the perivacuolar
compartment observed in mutants defective in MVB formation
that results from improper fusion of the endocytosed cargo with
the vacuole (Figure 5). These observations are consistent with the
fact that VipA causes defects in this pathway [13]. Similarly,
during macrophage infection translocated VipA associates with
host cell early endosomes and F-actin, often with the three
components forming large agglomerates (Figure 7). Moreover, and
in contrast to many characterized Icm/Dot substrates, the effector
is not found in the LCV (Figure 6). To rule out the possibility that
other T4SS substrates could mediate VipA subcellular localization
during infection, we analysed its distribution when ectopically
expressed in CHO cells and, therefore, in the absence other
Legionella proteins. In concordance with the previous results, we
observed VipA-EGFP association with cortical actin foci (Figure
S2) and with the early endosome marker EEA-1, demonstrating
that VipA does not require other bacterial factors to bind its
eukaryotic targets. In addition, no significant colocalization was
seen with later components of the Endosomal/MVB Pathway
(MVB component Alix and the lysosome) or the Secretory
Pathway (ER; Figure S3). The endocytic pathway is responsible
for the uptake of particles and converges in early endosomes,
where cargo sorting occurs and molecules targeted for degradation
in lysosomes are internalized to intraluminal vesicles originating
the MVB. This organelle subsequently travels to and fuses with
late endosomes and eventually lysosomes. Formation of the MVB
requires the Endosomal Complex Required for Transport
(ESCRT), and proteins belonging to the Alix/Bro1 family are
important components of the MVB, interacting with ESCRT
components to control the fission and fusion events taking place in
the endosome lumen in mammalian and yeast cells. In addition,
Alix associates with actin and several actin-binding proteins and is
involved in cytoskeleton assembly, being to date the only
eukaryotic link between actin dynamics and MVB formation
[52]. In this work, we found that Legionella VipA also connects
the two processes. The wild-type protein binds actin and promotes
growth of filaments in vitro, associates with host cell early
endosomes and actin filaments and leads to defects in the MVB
pathway when ectopically expressed in yeast. In contrast, the
VipA-1 mutant is unable to bind or polymerize actin, no longer
affects trafficking and displays a homogeneous cytosolic distribu-
tion. This shows that the ability of VipA to bind actin is related to
its association with a specific subcellular location as well as its role
in modulating organelle trafficking. In this context, our results are
consistent with a model where VipA, through its dual function of
regulating actin dynamics and binding to endosomal organelles,
may play a role in altering vesicle trafficking in order to enable the
pathogen to escape degradation. A possibility is a role in helping
isolating the LCV from the endocytic pathway, a process mediated
by Icm/Dot substrates [53]. This hypothesis is sustained by the
observation of large agglomerates of endosomal vesicles, F-actin
and VipA apart from the LCV during macrophage infection
(Figure 7).
To our knowledge, VipA is the only bacterial effector that binds
early endosomes and is implicated in actin dynamics in the host
cell. Thus, further characterization of its mode of action will
undoubtedly shed new light on the mechanisms employed not only
by L. pneumophila but also by other pathogens to manipulate host
cell pathways during infection.
Supporting Information
Figure S1 Effect of vipA in intracellular replication. A.
Immunoblot for VipA detection in cell extracts of L. pneumophila
strains. Lane 1, strain KS79 (DcomR); lane 2, LPIF3 (DcomR DvipA);
lane 3, 120 ng of purified His6-VipA. Equivalent amounts of cell
extracts were loaded in lanes 1 and 2. Immunodetection was
carried with a purified polyclonal antibody raised against His6-
VipA. B. Infection of A. castellanii with L. pneumophila strains KS79,
LPIF3 and dotA mutant carrying a plasmid containing a Ptac-GFP
fusion (pXDC31; [58]). Infection was carried out at a Multiplicity
of Infection (MOI) of 5. Replication was followed by time-course
fluorescence measurements for 72 hours.
(TIF)
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transiently transfected CHO-FccRII cells. CHO-FccRII
cells were transfected with plasmids expressing EGFP (pEGFP-
N1), VipA-EGFP (pIF203) or VipA-1-EGFP (pIF213). After
48 hours cells were fixed and actin filaments stained with
Rhodamine-phalloidin 5 mg.ml
21 (top panel), or pre-incubated
with Cytochalasin D 10 mM for 30 min (bottom panel) and
subsequently fixed and stained. For the micrograph of VipA-
EGFP and cytochalasin D, a plot is depicted showing the spatial
distribution and intensity of GFP and Rhodamine signal intensities
along the dashed line depicted. Representative images are shown.
(TIF)
Figure S3 Colocalization of VipA-EGFP and VipA-1-
EGFP with organelle markers in CHO-FccRII cells.
CHO-FccRII cells were transfected (see legend of Figure S2)
and observed after staining with antibodies against: A. Early
Endosomal (a-EEA-1); B. ER (a-KDEL); or C. Lysosome (a-
LAMP-1) or D. a-Alix. E. The fraction of VipA-GFP or VipA-1-
GFP colocalizing with each marker was quantified as described in
legend of Figure 7 (see also Materials and Methods for details).
Filled symbols represent cells expressing VipA-GFP, open symbols
cells expressing VipA-1-GFP, and bars indicate mean and
standard deviation. Statistical analysis was performed with
unpaired t test, and p values obtained are indicated (**, p,0.01;
***, p,0.001). Representative enlarged regions of analysed cells
(displayed in A, B, C and D) are shown below the graph.
(TIF)
Table S1 Strains used in this study.
(DOC)
Table S2 Plasmids and oligonucleotides used in this
study.
(DOC)
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